Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureRichard M. Stone
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML
10.1200/jco.23.01911 · 2024
A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
10.1158/2643-3230.bcd-22-0205 · 2023
Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML
10.1200/jco-25-00640 · 2025
Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML
10.1200/jco-25-00914 · 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
Kept as external metadata until matched
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020
Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
10.1002/ajh.27246
How I treat relapsed or refractory AML
10.1182/blood.2019001982 · 2020
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
10.1056/nejmoa1902688 · 2019
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
10.1056/nejmoa1716984 · 2018
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
10.1182/bloodadvances.2022009411 · 2023
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
10.1182/blood-2017-04-779405 · 2017
Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)
10.1200/jco.24.00826 · 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
10.1182/blood.2025028357 · 2025
Ziftomenib in relapsed or refractory NPM1-mutated AML
10.1200/jco-25-01694 · 2025
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00464-6 · 2023
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation
10.1056/nejmoa1614359 · 2017
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
2021
Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
10.1038/s41408-021-00603-3 · 2022
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
10.1038/nm.3788 · 2015
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
10.1182/blood.2023022480 · 2024
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
10.3324/haematol.2022.281927 · 2023
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
10.1038/s41408-025-01269-x · 2025
Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine
10.1200/jco.21.01546 · 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
10.1182/blood.2021014586 · 2022
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
10.1182/blood.2024024944 · 2024
Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia
10.1158/1078-0432.ccr-21-3405 · 2022
Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia
10.1056/nejmoa2117344 · 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
10.1080/10428194.2022.2136952 · 2023
No additional external references are available.